UEC just posted one of its sharpest single-week declines in recent memory, shedding 31% to close at $10.65 on Tuesday, with the move accelerating on June 9 when the stock dropped a further 15.5% on earnings day — and the question now is whether the short sellers who held firm into the print are quietly booking gains or repositioning for the next leg.
The short interest picture has shifted since Monday's preview note. Heading into the June 9 print, nearly 12% of the free float was sold short, with borrow costs around 0.51% and positions barely moving. Post-earnings, shorts trimmed more decisively: the position fell roughly 4.3% in a single session to 11.4% of free float, or about 55 million shares. That's the fastest one-day reduction in over a month, though it remains a high absolute level. What's notable is the structure of the lending market hasn't changed materially. Borrow costs have actually eased — down 23% on the week to 0.48% — and availability is running at 222% of outstanding short interest, comfortably above even the 52-week floor of 111%. With borrowing this cheap and the stock now 31% lower on the week, there is no mechanical pressure forcing shorts to cover. The ORTEX short score has eased from 65 to 62.75 over the past two weeks, a modest softening that reflects the slight unwind but no dramatic shift in positioning.
Options traders had been the canary in the coalmine. The put/call ratio edged up to 0.42 on June 9 — modestly above its 20-day mean of 0.40 by about 1.2 standard deviations — which, in context, was a subtle rather than dramatic warning. That same ratio sat at 0.37–0.39 through most of late May, so the tick higher into earnings was real but understated given the severity of the subsequent move. The 52-week range on the PCR runs from 0.15 to 0.79, meaning even the recent elevated reading is nowhere near the most defensive positioning UEC has seen. Call interest still dominated the options market heading into the report.
Analysts remain uniformly constructive, but the gap between their targets and the current price has widened dramatically. HC Wainwright reiterated its Buy and $26.75 target as recently as June 10 — the morning after the selloff — while TD Securities carried a $21 target from March. The mean analyst price target of $18.83 now implies roughly 77% upside from Tuesday's close. The bull case centres on Burke Hollow production, domestic uranium demand from the energy transition, and a well-funded balance sheet. The bear case is the company's own narrative: production delays at Irigaray, no near-term spot uranium sales planned, and a pre-revenue operational profile that makes valuation multiples unwieldy. The EV/EBITDA reading of 162x is not a number that comforts value buyers. UEC's EPS surprise factor score ranks in the 93rd percentile, but the 30-day EPS momentum score of just 14 suggests forward estimates have been drifting lower — a context that made any earnings-day miss more costly.
The peer group confirms this was a sector event, not a UEC-specific one. NXE fell 19.5% on the week, EFR dropped 25.9%, LTBR lost 24.5%, and ISO was the worst performer at -26.8%. CCO — the sector bellwether — shed 14.6%. The breadth and uniformity of the selloff points to a macro or sector-level repricing of uranium equities rather than a company-specific earnings miss playing out in isolation.
The next scheduled earnings event is September 24. Between now and then, the key variables to watch are whether the short interest — still at a structurally elevated 11.4% of free float with very cheap borrow — continues its slow bleed or stabilises, and whether spot uranium pricing gives analysts any reason to revise those $18–$27 targets toward current market levels.
See the live data behind this article on ORTEX.
Open UEC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
